worthy

Pfizer: Dividend Yield Makes It a Haven in This Market

Recall the late 90's when Pfizer briefly touched $50 with a multiple somewhat similar, and almost any drug analyst one listened to back in 1999 felt that Pfizer with its compelling pipeline was expensive for a good reason, and that its future growth was assured. Shift forward 9-10 years and we find the sentiment just the opposite. Back in '99 it was "Viagara all the way". Today it's "no pipeline to replace Lipitor". If this isn't a contrarian's delight, I don't know what one is! I own this stock.